A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body
Clinical trial NCT06421636 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06421636
- Sponsor
- Regeneron Pharmaceuticals
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-09-30
- Primary completion
- 2026-12-03
- Enrollment
- 19
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.